Home >> Pharmaceuticals >> Food & Beverage >>

Global Urological Cancer Drugs Market Professional Survey Report 2018

Published: Jan-2019 | Format: PDF | XYZResearch | Number of pages: 117 | Code: MRS - 433400

This report focuses on top manufacturers in global market, with Sales, price, revenue and market share for each manufacturer, covering
      Novartis
      Pfizer
      Johnson & Johnson
      AstraZeneca
      Astellas
      Bristol-Myers Squibb
      Abbott Laboratories
      Celgene Corporation
      Dendreon Corporation
      Ferring Pharmaceuticals
      GlaxoSmithKline
      Indevus Pharmaceuticals Inc
      Ipsen
      Roche Healthcare
      Sanofi S.A.
    ...

On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
     Xofigo (Radium Ra 223 Dichloride)
      Jevtana (Cabazitaxel)
      Inlyta (Axitinib)
      Votrient (Pazopanib Hydrochloride)
      Sutent (Sunitinib Malate)
      Zytiga (Abiraterone Acetate)
    ? ? Xtandi (Enzalutamide)
    ? ? Opdivo (Nivolumab)
    ? ? Provenge (Sipuleucel-T)

By Application, the market can be split into
    China
    USA
    Europe
    Japan
    Korea
    India
    Southeast Asia
    South America

By Regions, this report covers (we can add the regions/countries as you want)

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

Global Urological Cancer Drugs Market Professional Survey Report 2017
1 Report Overview
    1.1 Definition and Specification
    1.2 Report Overview
        1.2.1 Manufacturers Overview
        1.2.2 Regions Overview
        1.2.3 Type Overview
        1.2.4 Application Overview
    1.3 Industrial Chain
        1.3.1 Urological Cancer Drugs Overall Industrial Chain
        1.3.2 Upstream
        1.3.3 Downstream
    1.4 Industry Situation
        1.4.1 Industrial Policy
        1.4.2 Product Preference
        1.4.3 Economic/Political Environment
    1.5 SWOT Analysis
2 Market Analysis by Types
    2.1 Overall Market Performance(Volume)
             2.1.1  Xofigo (Radium Ra 223 Dichloride) Market Performance (Volume)
             2.1.2   Jevtana (Cabazitaxel) Market Performance (Volume)
             2.1.3   Inlyta (Axitinib) Market Performance (Volume)
             2.1.4   Votrient (Pazopanib Hydrochloride) Market Performance (Volume)
             2.1.5   Sutent (Sunitinib Malate) Market Performance (Volume)
    2.2 Overall Market Performance(Value)
             2.1.1  Xofigo (Radium Ra 223 Dichloride) Market Performance (Value)
             2.1.2   Jevtana (Cabazitaxel) Market Performance (Value)
             2.1.3   Inlyta (Axitinib) Market Performance (Value)
             2.1.4   Votrient (Pazopanib Hydrochloride) Market Performance (Value)
             2.1.5   Sutent (Sunitinib Malate) Market Performance (Value)
3 Product Application Market
    3.1 Overall Market Performance (Volume)
             3.1.1  Prostate Cancer Market Performance (Volume)
             3.1.2   Bladder Cancer Market Performance (Volume)
             3.1.3   Kidney Cancer Market Performance (Volume)
             3.1.4   Testicular Cancer Market Performance (Volume)
4 Manufacturers Profiles/Analysis
    4.1   Novartis 
        4.1.1   Novartis Profiles 
        4.1.2   Novartis Product Information 
        4.1.3   Novartis Urological Cancer Drugs Business Performance  
        4.1.4   Novartis Urological Cancer Drugs Business Development and Market Status  
    4.2   Pfizer 
        4.2.1   Pfizer Profiles 
        4.2.2   Pfizer Product Information 
        4.2.3   Pfizer Urological Cancer Drugs Business Performance  
        4.2.4   Pfizer Urological Cancer Drugs Business Development and Market Status  
    4.3   Johnson & Johnson 
        4.3.1   Johnson & Johnson Profiles 
        4.3.2   Johnson & Johnson Product Information 
        4.3.3   Johnson & Johnson Urological Cancer Drugs Business Performance  
        4.3.4   Johnson & Johnson Urological Cancer Drugs Business Development and Market Status  
    4.4   AstraZeneca 
        4.4.1   AstraZeneca Profiles 
        4.4.2   AstraZeneca Product Information 
        4.4.3   AstraZeneca Urological Cancer Drugs Business Performance  
        4.4.4   AstraZeneca Urological Cancer Drugs Business Development and Market Status  
    4.5   Astellas 
        4.5.1   Astellas Profiles 
        4.5.2   Astellas Product Information 
        4.5.3   Astellas Urological Cancer Drugs Business Performance  
        4.5.4   Astellas Urological Cancer Drugs Business Development and Market Status  
    4.6   Bristol-Myers Squibb 
        4.6.1   Bristol-Myers Squibb Profiles 
        4.6.2   Bristol-Myers Squibb Product Information 
        4.6.3   Bristol-Myers Squibb Urological Cancer Drugs Business Performance  
        4.6.4   Bristol-Myers Squibb Urological Cancer Drugs Business Development and Market Status  
    4.7   Abbott Laboratories 
        4.7.1   Abbott Laboratories Profiles 
        4.7.2   Abbott Laboratories Product Information 
        4.7.3   Abbott Laboratories Urological Cancer Drugs Business Performance  
        4.7.4   Abbott Laboratories Urological Cancer Drugs Business Development and Market Status  
    4.8   Celgene Corporation 
        4.8.1   Celgene Corporation Profiles 
        4.8.2   Celgene Corporation Product Information 
        4.8.3   Celgene Corporation Urological Cancer Drugs Business Performance  
        4.8.4   Celgene Corporation Urological Cancer Drugs Business Development and Market Status  
    4.9   Dendreon Corporation 
        4.9.1   Dendreon Corporation Profiles 
        4.9.2   Dendreon Corporation Product Information 
        4.9.3   Dendreon Corporation Urological Cancer Drugs Business Performance  
        4.9.4   Dendreon Corporation Urological Cancer Drugs Business Development and Market Status  
    4.10   Ferring Pharmaceuticals 
        4.10.1   Ferring Pharmaceuticals Profiles 
        4.10.2   Ferring Pharmaceuticals Product Information 
        4.10.3   Ferring Pharmaceuticals Urological Cancer Drugs Business Performance  
        4.10.4   Ferring Pharmaceuticals Urological Cancer Drugs Business Development and Market Status  
    4.11   GlaxoSmithKline 
    4.12   Indevus Pharmaceuticals Inc 
    4.13   Johnson & Johnson 
    4.14   AstraZeneca 
    4.15   Astellas 
5 Market Performance for Manufacturers
    5.1 Global Urological Cancer Drugs Capacity (K Units) and Market Share by Manufacturers 2013-2018
    5.2 Global Urological Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    5.3 Global Urological Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    5.4 Global Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
    5.5 Global Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
    5.6 Market Concentration
6 Regions Market Performance for Manufacturers
    6.1 China Market Performance for Manufacturers
        6.1.1 China Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.1.2 China Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.1.3 China Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.1.4 China Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.1.5 Market Concentration
    6.2 USA Market Performance for Manufacturers
        6.2.1 USA Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.2.2 USA Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.2.3 USA Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.2.4 USA Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.2.5 Market Concentration
    6.3 Europe Market Performance for Manufacturers
        6.3.1 Europe Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.3.2 Europe Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.3.3 Europe Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.3.4 Europe Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.3.5 Market Concentration
    6.4 Japan Market Performance for Manufacturers
        6.4.1 Japan Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.4.2 Japan Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.4.3 Japan Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.4.4 Japan Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.4.5 Market Concentration
    6.5 Korea Market Performance for Manufacturers
        6.5.1 Korea Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.5.2 Korea Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.5.3 Korea Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.5.4 Korea Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.5.5 Market Concentration
    6.6 India Market Performance for Manufacturers
        6.6.1 India Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.6.2 India Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.6.3 India Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.6.4 India Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.6.5 Market Concentration
    6.7 Southeast Asia Market Performance for Manufacturers
        6.7.1 Southeast Asia Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.7.2 Southeast Asia Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.7.3 Southeast Asia Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.7.4 Southeast Asia Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.7.5 Market Concentration
    6.8 South America Market Performance for Manufacturers
        6.8.1 South America Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.8.2 South America Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.8.3 South America Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.8.4 South America Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.8.5 Market Concentration
7 Global  Urological Cancer Drugs Market Performance (Sales Point)
    7.1 Global Urological Cancer Drugs Capacity (K Units) and Market Share by Regions 2013-2018
    7.2 Global Urological Cancer Drugs Sales (K Units) and Market Share by Regions 2013-2018
    7.3 Global Urological Cancer Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    7.4 Global Urological Cancer Drugs Price (USD/Unit) by Regions 2013-2018
    7.5 Global Urological Cancer Drugs Gross Margin by Regions 2013-2018
8 Development Trend for Regions (Sales Point)
    8.1 Global Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.2 China Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.3 USA Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.4 Europe Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.5 Japan Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.6 Korea Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.7 India Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.8 Southeast Asia Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
    8.9 Southeast Asia Urological Cancer Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
9 Development Trend for Regions (Sales Point)
    9.1 Global Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.2 China Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.3 USA Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.4 Europe Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.5 Japan Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.6 Korea Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.7 India Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.8 Southeast Asia Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    9.9 South America Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
10 Upstream Source, Technology and Cost
    10.1 Upstream Source
    10.2 Technology
    10.3 Cost
11 Channel Analysis
    11.1 Market Channel
    11.2 Distributors
12 Consumer Analysis
    12.1  Prostate Cancer Industry 
    12.2   Bladder Cancer Industry 
    12.3   Kidney Cancer Industry 
13 Market Forecast 2019-2024
    13.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
        13.1.1 Global Urological Cancer Drugs Capacity (K Units) and Share by Regions 2019-2024
        13.1.2 Global Urological Cancer Drugs Capacity (K Units), Sales (K Units) and Growth Rate 2019-2024
        13.1.3 China Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.4 USA Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.5 Europe Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.6 Japan Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.7 Korea Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.8 India Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.9 Southeast Asia Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.1.10 South America Urological Cancer Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    13.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
        13.3.1 Overall Market Performance
        13.3.2  Xofigo (Radium Ra 223 Dichloride) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.3.3   Jevtana (Cabazitaxel) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.3.4   Inlyta (Axitinib) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        13.3.5   Votrient (Pazopanib Hydrochloride) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    13.4 Sales by Application 2019-2024
        13.4.1 Overall Market Performance
        13.4.2  Prostate Cancer Sales and and Growth Rate 2019-2024
        13.4.3   Bladder Cancer Sales and and Growth Rate 2019-2024
        13.4.4   Kidney Cancer Sales and and Growth Rate 2019-2024
        13.4.5   Testicular Cancer Sales and and Growth Rate 2019-2024
    13.5 Price (USD/Unit) and Gross Profit
        13.5.1 Global Urological Cancer Drugs Price (USD/Unit) Trend 2019-2024
        13.5.2 Global Urological Cancer Drugs Gross Profit Trend 2019-2024
14 Conclusion



                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2800 View Pricing